Key result
Lumateperone nightly remitted aggression and hostility in two 18-year-old males with autism spectrum disorder and intermittent explosive disorder within 10 to 30 days.
Why the study?
The use of lumateperone in reducing aggression in patients with autism spectrum disorder and intermittent explosive disorder had not previously been described.
Does lumateperone reduce aggression in patients with autism spectrum disorder and intermittent explosive disorder?
Case Report (n=2)
Does lumateperone reduce aggression in patients with autism spectrum disorder and intermittent explosive disorder?
Lumateperone may be effective in reducing aggression and hostility in patients with autism spectrum disorder and intermittent explosive disorder.
Answers are grounded in this paper and cite their sources.
Hypothesis-generating for lumateperone in ASD with IED; prospective trials needed before clinical adoption.
The use of lumateperone in reducing aggression in patients with autism spectrum disorder (ASD) and intermittent explosive disorder (IED) has not heretofore been described. Case 1 is a non-verbal 18-year-old male with autism who presented with anger and aggression, biting his hands, intermittently grunting, and screaming. The patient's hostility subsided after ten days of establishing lumateperone 42 mg nightly, in cross-titration with aripiprazole. Case 2 is a non-verbal 18-year-old male with a history of hypsarrhythmia, and Lennox-Gastaut syndrome, presented with similar aggression coincident increase in the frequency of myoclonic seizures. Management was initiated with 42 mg of lumateperone nightly. Aggression and hostility were remitted after ten days and one month, respectively, for cases 1 and 2; however, the seizures persisted in Case 2. Due to its dual action on dopamine D2 receptors and better side effect profile compared to other antipsychotics, the authors encourage a trial of lumateperone in treating aggression associated with ASD and IED.
No takes yet. Share an insight, caveat, or question.
Mehdiratta et al. (2023) conducted a case report in Autism spectrum disorder and intermittent explosive disorder (n=2). Lumateperone was evaluated on Reduction in aggression and hostility. Lumateperone nightly remitted aggression and hostility in two 18-year-old males with autism spectrum disorder and intermittent explosive disorder within 10 to 30 days.
Synapse has enriched 10 related papers. Consider them for comparative context: